Current status of single-course antenatal steroid therapy

Clinical Obstetrics and Gynecology

Volumn 46, Issue 1, 2003, Pages 132-149

  Dudley, Donald J ^a   Waters, Thaddeus P ^b   Nathanielsz, Peter W ^c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; GLUCOCORTICOID; SURFACTANT;

CARDIOVASCULAR RESPONSE; DRUG EFFECT; DRUG EXCRETION; DRUG METABOLISM; FETUS GROWTH; FETUS LUNG MATURATION; FETUS MOVEMENT; HEART RATE; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMMUNE SYSTEM; NEWBORN DEATH; NEWBORN INFECTION; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURE LABOR; PRENATAL DRUG EXPOSURE; REVIEW; RISK BENEFIT ANALYSIS; STEROID THERAPY; TREATMENT CONTRAINDICATION;

DRUG ADMINISTRATION SCHEDULE; FEMALE; FETAL DISEASES; GLUCOCORTICOIDS; HUMANS; LUNG; PREGNANCY; PRENATAL CARE; PULMONARY SURFACTANTS;

EID: 0037676344     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003081-200303000-00018     Document Type: Review

References (101)

1. NIH Consensus Development Panel. Effect of corticosteroids for fetal maturation on perinatal outcomes. JAMA. 1995;273:413-418.
2. Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment of prevention of the respiratory distress syndrome in premature infants. Pediatrics. 1972;50:515-525.
3. Ballard PL. Hormonal regulation of pulmonary surfactant. Endocrine Rev. 1989;10:165-181.
4. Dulkerian SJ, Gonzales LW, Ballard PL. Developmental and hormonal regulation of surfactant protein D mRNA in human lung [abstract]. Pediatr Res. 1994;35:66A.
5. Venkatesh VC, Ballard PL, Ertsey R, Iannuzzi DM. Glucocorticoid regulation of the genes for pulmonary surfactant proteins SP-B and SP-C. Am J Respir Cell Mol Biol. 1993;8:222-228.
6. Iannuzzi DM, Ertsey R, Ballard PL. Biphasic glucocorticoid regulation of pulmonary surfactant protein-A: characterization of the inhibitory process. Am J Physiol. 1993;264:L236-244.
7. Gonzales LW, Ertsey R, Ballard PL, et al. Glucocorticoid stimulation of fatty acid synthesis in explants of human fetal lung. Biochim Biophys Acta. 1990;1042:1-12.
8. Ballard PL, Ballard RA. Scientific basis and therapeutic regimens for use of antenatal glucocorticoids. Am J Obstet Gynecol. 1995;173:254-262.
9. Ballard PL. Hormones and lung maturation. In: Monographs on endocrinology, Vol 28. Berlin: Springer-Verlag, 1986:1345.
10. Ballard PL, Granberg JP, Ballard RA. Glucocorticoid levels in maternal and cord serum after prenatal betamethasone therapy to prevent respiratory distress syndrome. J Clin Invest. 1975;56:1548-1554.
11. Petersen MC, Collier CB, Ashley JJ, et al. Disposition of betamethasone in parturient women after intravenous administration. Eur J Clin Pharmacol. 1983;25:803-810.
12. Miyachi Y, Yotsumoto H, Kano T, et al. Blood levels of synthetic glucocorticoids after administration by various routes. J Endocrinol. 1979;82:149-157.
13. Petersen MC, Nation RL, Ashley JJ, McBride WG. The placental transfer of betamethasone. Eur J Clin Pharmacol. 1980;18:245-247.
14. Anderson ABM, Gennser G, Jermey JY, et al. Placental transfer and metabolism of betamethasone in human pregnancy. Obstet Gynecol. 1977;49:471-474.
15. Blanford AT, Murphy BEP. In vitro metabolism of prednisolone, dexamethasone, betamethasone and cortisol by the human placenta. Am J Obstet Gynecol. 1977;127:264-267.
16. Levitz M, Jansen V, Dancis J. The transfer and metabolism of corticosteroids in the perfused human placenta. Am J Obstet Gynecol. 1978;132:363-366.
17. Lo ES, Huttinot G, Fein M, Cooper TB. Direct radioimmunoassay procedure for plasma dexamethasone with a sensitivity at picogram level. J Pharm Sci. 1989;78:1040-1044.
18. Post M, Smith BT. Hormonal control of surfactant metabolism. In: Robertson B, Van Golde LMG, Batenburg JJ, eds. Pulmonary surfactant. Amsterdam: Elsevier Science Publishers, 1992:379-424.
19. Ikegami M, Berry D, Elkady T, et al. Corticosteroids and surfactant change lung function and protein leaks in the lungs of ventilated premature rabbits. J Clin Invest. 1987;79:1371-1378.
20. Snyder JM, Johnston JM, Mendelson CR. Differentiation of type II cells of human fetal lung in vitro. Cell Tissue Res. 1981;220:17-25.
21. Frank L, Lewis PL, Sosenko IRS. Dexamethasone stimulation of fetal rat lung antioxidant enzyme activity in parallel with surfactant stimulation. Pediatrics. 1985;75:569-574.
22. O'Brodovich H, Canessa C, Ueda J, et al. Expression of the epithelial Na+ channel in the developing rat lung. Am J Physiol. 1993;34:C491-496.
23. Celsi G, Wang Z-M, Akusjarvi G, Aperia A. Sensitive periods for glucocorticoids' regulation of Na+, K+-ATPase mRNA in the developing lung and kidney. Pediatr Res. 1993;33:5-9.
24. Ballard PL. Glucocorticoids and differentiation. In: Baxter JD, Rousseau GG, eds. Glucocorticoid hormone action. Heidelberg: Springer-Verlag, 1979:493-515.
25. Liggins GC. Adrenocortical-related maturational events in the fetus. Am J Obstet Gynecol. 1976;126:931-941.
26. Stein HM, Oyama K, Martinez A, et al. Effects of corticosteroids in preterm sheep on adaptation and sympathoadrenal mechanisms at birth. Am J Physiol. 1993;264:E763-769.
27. Wang Z-M, Celsi G. Glucocorticoids differentially regulate the mRNA for Na+, K+-ATPase isoforms in infant rat heart. Pediatr Res. 1993;33:1-4.
28. Christensen HD, Sienko AE, Rayburn WF, et al. A placebo-controlled, blinded comparison between betamethasone and dexamethasone to enhance lung maturation in the fetal mouse. J Soc Gynecol Investig. 1997;4:130-134.
29. Rayburn WF, Christensen HD, Gonzalez CL. A placebo-controlled comparison between betamethasone and dexamethasone for fetal maturation: differences in neurobehavioral development of mice offspring. Am J Obstet Gynecol. 1997;176:842-851.
30. Eliman A, Verma U, Beneck D, et al. Histologic chorioamnionitis, antenatal steroids, and perinatal outcomes. Obstet Gynecol. 2000;96:333-336.
31. Crowley P. Prophylactic corticosteroids for preterm birth (Cochrane Review). In: The Cochrane Library, Issue 3, 2002. Oxford: Update Software.
32. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome. Am J Obstet Gynecol. 1981;141:276-287.
33. Wright LL, Horbar JD, Gunkel H, et al. Evidence from multicenter networks on the current use and effectiveness of antenatal corticosteroids in low birthweight infants. Am J Obstet Gynecol. 1995;173:263-269.
34. Canterino JC, Verma U, Visintainer PF, et al. Antenatal steroids and periventricular leukomalacia. Obstet Gynecol. 2001;97:135-139.
35. Agarwal R, Chiswick ML, Rimmer S, et al. Antenatal steroids are associated with a reduction in the incidence of cerebral white matter lesions in very low birthweight infants. Arch Dis Child Fetal Neonatal Ed. 2002;86:F96-101.
36. Baud O, Foix-L'Helias L, Kaminski M, et al. Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very premature infants. N Engl J Med. 1999;341:1190-1196.
37. White A, Marcucci G, Andrews E, et al. Antenatal steroids and neonatal outcomes in controlled clinical trials of surfactant replacement. The American Exosurf Neonatal Study Group I and The Canadian Exosurf Neonatal Study Group. Am J Obstet Gynecol. 1995;173:286-290.
38. Farrell EE, Silver RK, Kimberlin LV, et al. Impact of antenatal dexamethasone on respiratory distress syndrome in surfactanttreated infants. Am J Obstet Gynecol. 1989;161:628-633.
39. Kwong MS, Egan EA, Notter RA. Synergistic responses of antenatal betamethasone and tracheal instillation of calf lung surfactant extract at birth [abstract]. Pediatr Res. 1986;21:458.
40. Jobe AH, Mitchell BR, Gunkel JH. Beneficial effects of the combined use of prenatal corticosteroids and postnatal surfactant on preterm infants. Am J Obstet Gynecol. 1993;168:508-513.
41. Warner BB, Kiely JL, Donovan EF. Multiple births and outcome. Clin Perinatol. 2000;27:347-361.
42. Joseph KS, Allen AC, Dodds L, et al. Causes and consequences of recent increases in preterm birth among twins. Obstet Gynecol. 2001;98:57-64.
43. Donovan EF, Ehrenkranz RA, Shankaran S, et al. Outcomes of very low birth weight twins cared for in the National Institute of Child Health and Human Development Neonatal Research Network's intensive care units. Am J Obstet Gynecol. 1998;179:742-749.
44. Murphy DJ, Caukwell S, Joels LA, Wardle P. Cohort study of the neonatal outcome of twin pregnancies that were treated with prophylactic or rescue antenatal corticosteroids. Am J Obstet Gynecol. 2002;187:483-488.
45. Ardila J, Le Guennec J, Papageorgiou A. Influence of antenatal betamethasone and gender cohabitation on outcome of twin pregnancies 24 to 34 weeks of gestation. Semin Perinatol. 1994;18:15-18.
46. Spinillo A, Capuzzo E, Ometto A, et al. Value of antenatal corticosteroid therapy in preterm birth. Early Hum Dev. 1995;42:37-47.
47. Turrentine MA, Dupras-Wilson P, Wilkins IA. A retrospective analysis of the effect of antenatal steroid administration on the incidence of respiratory distress syndrome in preterm twin pregnancies. Am J Perinatol. 1996;13:351-354.
48. Quist-Therson EC, Myhr TL, Ohlsson A. Antenatal steroids to prevent respiratory distress syndrome: multiple gestation as an effect modifier. Acta Obstet Gynecol Scand. 1999;78:388-392.
49. Ballabh P, Lo ES, Kumari J, et al. Pharmacokinetics of betamethasone in twin and singleton pregnancy. Clin Pharmacol Ther. 2002;71:39-45.
50. McElrath TF, Norwitz ER, Nour N, Robinson JN. Contemporary trends in the management of delivery at 23 weeks' gestation. Am J Perinatol. 2002;19:9-15.
51. Hack M. Outcomes of children of extremely low birthweight and gestational age in the 1990s. Early Human Dev. 1999;53:193-218.
52. Allen MC, Donohue PK, Dusman AE. The limit of viability: neonatal outcome of infants born at 22 to 25 weeks' gestation. N Engl J Med. 1993;329:1597-1601.
53. Perinatal care at the threshold of viability. American Academy of Pediatrics Committee on Fetus and Newborn. American College of Obstetricians and Gynecologists Committee on Obstetric Practice. Pediatrics. 1995;96:974-976.
54. Draper ES, Manktelow B, Field DJ, James D. Prediction of survival for preterm births by weight and gestational age: retrospective population based study. Br Med J. 1999;319:1093-1097.
55. Emsley HCA, Wardle SP, Sims DG, et al. Increased survival and deteriorating developmental outcomes in 23- to 25-week-old gestation infants, 1990-4 compared with 1984-9. Arch Dis Child. 1998;78:99-104.
56. Hussain N, Galal M, Ehrenkranz RA, et al. Pre-discharge outcomes of 22-27 weeks' gestational age infants born at tertiary care centers in Connecticut implications for perinatal management. Conn Med. 1998;62:131-137.
57. O'Shea TM, Kleinpeter KL, Goldstein DJ, et al. Survival and developmental disability in infants with birth weights of 501 to 800 g, born between 1979 and 1994. Pediatrics. 1997;100:982-986.
58. Kramer WB, Saade GR, Goodrum L, et al. Neonatal outcome after active perinatal management of the very premature infant between 23 and 27 weeks' gestation. J Perinatol. 1997;17:439-443.
59. Holtrop PC, Ertzbischoff LM, Roberts CL, et al. Survival and short-term outcome in newborns of 23 to 25 weeks' gestation. Am J Obstet Gynecol. 1994;170:1266-1270.
60. Stevenson DK, Wright LI, Lemons JA, et al. Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, January 1993 through December 1994. Am J Obstet Gynecol. 1998;179:1632-1639.
61. Wood NS, Marlow N, Costeloe K, et al. Neurologic and developmental disability after extremely preterm birth. N Engl J Med 2000;343:378-384.
62. McElrath TF, Robinson JN, Ecker JL, et al. Neonatal outcome of infants born at 23 weeks' gestation. Obstet Gynecol. 2001;97:49-55.
63. Helal KJ, Gordon MC, Lightner CR, et al. Adrenal suppression induced by betamethasone in women at risk for premature delivery. Obstet Gynecol. 2000;96:287-290.
64. Uno H, Eisele S, Sakai A, et al. Neurotoxicity of glucocorticoids in the primate brain. Horm Behav. 1994;28:336-348.
65. Docherty CC, Kalmar-Nagy J, Engelen M, et al. Effect of in vivo fetal infusion of dexamethasone at 0.75 GA on fetal ovine resistance artery responses to ET-1. Am J Physiol Regul Integr Comp Physiol. 2001;281:R261-268.
66. Anwar MA, Schwab M, Poston L, et al. Betamethasone-mediated vascular dysfunction and changes in hematological profile in the ovine fetus. Am J Physiol. 1999;276:H1137-1143.
67. Schwab M, Roedel M, Anwar MA, et al. Effects of betamethasone administration to the fetal sheep in late gestation on fetal cerebral blood flow. J Physiol. 2000;528:619-632.
68. Derks JB, Giussani DA, Jenkins SL, et al. A comparative study of cardiovascular, endocrine, and behavioral effects of betamethasone and dexamethasone administration to the fetal sheep. J Physiol. 1997;499:217-226.
69. Rotmensch S, Liberati M, Vishne T, et al. The effect of betamethasone and dexamethasone on fetal heart rate patterns and biophysical properties. A prospective randomized trial. Acta Obstet Gynecol Scand. 1999;78:493-500.
70. Mulder EJ, Derks JB, Visser GH. Antenatal corticosteroid therapy and fetal behavior: a randomised study of the effects of betamethasone and dexamethasone. Br J Obstet Gynaecol. 1997;104:1239-1247.
71. Coleman MAG, France JT, Schellenberg JC, et al. Corticotrophin-releasing hormone, corticotrophin-releasing hormonebinding globulin, and activin A in maternal serum: prediction of preterm delivery and response to glucocorticoids in women with symptoms of preterm labor. Am J Obstet Gynecol. 2000;183:643-648.
72. Jeffray TM, Marioni E, Ramirez M, et al. Effect of prenatal betamethasone administration on maternal and fetal corticosteroidbinding globulin concentrations. Am J Obstet Gynecol. 1999;181:1546-1551.
73. Derks JB, Mulder EJ, Visser GH. The effects of maternal betamethasone administration on the fetus. Br J Obstet Gynaecol. 1995;102:40-46.
74. Senat MV, Minoui S, Multon O, et al. Effect of dexamethasone and betamethasone on fetal heart rate variability in preterm labor: a randomised study. Br J Obstet Gynaecol. 1998;105:749-755.
75. Magee LA, Dawes GS, Moulden M, Redman CW. A randomised controlled comparison of betamethasone with dexamethasone: effects on the antenatal fetal heart rate. Br J Obstet Gynaecol. 1997;104:1233-1238.
76. Salokorpi T, Sajaniemi N, Hallback H, et al. Randomized study of the effect of antenatal dexamethasone on growth and development of premature children at the corrected age of 2 years. Acta Paediatr. 1997;86:294-298.
77. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal steroid administration on the infant: long-term follow-up. J Pediatr. 1984;104:259-267.
78. Howie RN, Liggins GC. The New Zealand study of antepartum glucocorticoid treatment. In: Farrel PM, ed. Lung development: Biological and clinical perspectives, II. New York: Academic Press, 1982;255-265.
79. Smolders-deHaas H, Neuvel J, Schmand B, et al. Physical development and medical history of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome: a 10-12 year follow-up. Pediatrics. 1990;86:65-70.
80. Kavanagh J, Kelly AJ, Thomas J. Corticosteroids for induction of labor. Cochrane Database of Systematic Reviews. (2):CD003100, 2001.
81. Elliott JP, Radin TG. The effect of corticosteroid administration on uterine activity and preterm labor in high-order multiple gestations. Obstet Gynecol. 1995;85:250-254.
82. Brown MS, Kovanen PT, Goldstein JL. Receptor-mediated uptake of lipoprotein-cholesterol and its utilization for steroid synthesis in the adrenal cortex. Recent Prog Horm Res. 1978;35:215-257.
83. Carr BR, Simpson ER. Lipoprotein utilization and cholesterol synthesis by the human fetal adrenal gland. Endocr Rev. 1981;2:306-326.
84. Andersen GE, Friis-Hansen B. Cord serum lipid and lipoprotein-cholesterol values in normal and betamethasone-treated newborns of varying gestational age. Acta Paediatr Scand. 1977;66:355-360.
85. Parker CR Jr, MacDonald PC, Carr BR, Morrison JC. The effects of dexamethasone and anencephaly on newborn serum levels of apolipoprotein A-1. J Clin Endocrinol Metab. 1987;65:1098-1101.
86. Parker CR Jr, Atkinson MW, Owen J, Andrews WW. Dynamics of the fetal adrenal, cholesterol, and apolipoprotein B responses to antenatal betamethasone therapy. Am J Obstet Gynecol. 1996;174:562-565.
87. Cupps TR, Fauci AS. Corticosteroid-mediated immunoregulation in man. Immunol Rev. 1982;65:133-155.
88. Barak M, Cohen A, Hershkowitz S. Total leukocyte and neutrophil count changes associated with antenatal betamethasone administration in preterm infants. Acta Paediatr. 1992;81:760-763.
89. Eisenfeld L, Rosenkrantz TS, Block C, et al. Effect of corticosteroids on the maturation of neutrophil motility in very low birthweight neonates. Am J Perinatol. 1994;11:163-166.
90. Kavelaars A, Van Der Pompe G, Bakker JM, et al. Altered immune function in human newborns after prenatal administration of betamethasone: enhanced natural killer cell activity and decreased T cell proliferation in cord blood. Pediatr Res. 1999;45:306-312.
91. Chabra S, Cottrill C, Rayens MK, et al. Lymphocyte subsets in cord blood of preterm infants: effect of antenatal steroids. Biol Neonate. 1998;74:200-207.
92. Sloboda DM, Moss TJ, Gurrin LC, et al. The effect of prenatal betamethasone administration on postnatal ovine hypothalamicpituitary-adrenal function. J Endocrinol. 2002;172:71-81.
93. Schaap AH, Wolf H, Bruinse HW, et al. Effects of antenatal corticosteroid administration on mortality and long-term morbidity in early preterm, growth-restricted infants. Obstet Gynecol. 2001;97:954-960.
94. Smith JT, Waddell BJ. Increased fetal glucocorticoid exposure delays puberty onset in postnatal life. Endocrinology. 2000;1141:2422-2428.
95. Barker DJ. Fetal origins of cardiovascular disease. Ann Intern Med. 1999;31:3-6.
96. Benediktsson R, Lindsay RS, Noble J, et al. Glucocorticoid exposure in utero: new model for adult hypertension. Lancet. 1993;341:339-341.
97. Seckl JR, Cleasby M, Nyrirenda MJ. Glucocorticoids, 11β-hydroxysteroid dehydrogenase, and fetal programming. Kidney Int. 2000;57:1414-1417.
98. Dodic M, Hantzis V, Duncan J, et al. Programming effects of short prenatal exposure to cortisol. FASEB J. 2002;16:1017-1026.
99. Molnar J, Nijland MJ, Howe DC, et al. Evidence for microvascular dysfunction after prenatal dexamethasone at 0.7, 0.75, and 0.8 gestation in sheep. Am J Physiol Regul Integr Comp Physiol. 2002;283:R561-567.
100. Goland RS, Jozak S, Warren WB, et al. Elevated levels of umbilical cord plasma corticotrophin-releasing hormone in growth-retarded fetuses. J Clin Endocrinol Metab. 1993;77:1174-1179.
101. Phillips DI, Fall CHD, Whorwood CB, et al. Elevated plasma cortisol concentrations: an explanation for the relationship between low birth weight and adult cardiovascular risk factors. J Clin Endocrinol Metab. 1998;83:757-760.